AMED Quote, Financials, Valuation and Earnings

Health Catalyst has a net margin of -3.41% compared to Amedisys's net margin of -25.97%. Amedisys's return on equity of 3.71% beat Health Catalyst's return on equity of -19.29%.

Amedisys has a consensus price target of $96.86, signalling upside risk potential of 5.86%. On the other hand Health Catalyst has an analysts' consensus of $8.45 which suggests that it could grow by 120.75%. Given that Health Catalyst has higher upside potential than Amedisys, analysts believe Health Catalyst is more attractive than Amedisys.

Amedisys has a beta of 0.890, which suggesting that the stock is 11.035% less volatile than S&P 500. In comparison Health Catalyst has a beta of 1.435, suggesting its more volatile than the S&P 500 by 43.508%.

Amedisys has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Health Catalyst offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amedisys pays -- of its earnings as a dividend. Health Catalyst pays out -- of its earnings as a dividend.

Amedisys quarterly revenues are $598.1M, which are larger than Health Catalyst quarterly revenues of $79.6M. Amedisys's net income of -$20.4M is higher than Health Catalyst's net income of -$20.7M. Notably, Amedisys's price-to-earnings ratio is 69.85x while Health Catalyst's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amedisys is 1.29x versus 0.75x for Health Catalyst. Usually stocks with elevated PS ratios are considered overvalued.

Humana has a net margin of -3.41% compared to Amedisys's net margin of -2.37%. Amedisys's return on equity of 3.71% beat Humana's return on equity of 7.25%.

Amedisys has a consensus price target of $96.86, signalling upside risk potential of 5.86%. On the other hand Humana has an analysts' consensus of $300.75 which suggests that it could grow by 3.62%. Given that Amedisys has higher upside potential than Humana, analysts believe Amedisys is more attractive than Humana.

Amedisys has a beta of 0.890, which suggesting that the stock is 11.035% less volatile than S&P 500. In comparison Humana has a beta of 0.624, suggesting its less volatile than the S&P 500 by 37.637%.

Amedisys has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Humana offers a yield of 1.22% to investors and pays a quarterly dividend of $0.89 per share. Amedisys pays -- of its earnings as a dividend. Humana pays out 35.71% of its earnings as a dividend. Humana's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Amedisys quarterly revenues are $598.1M, which are smaller than Humana quarterly revenues of $29.2B. Amedisys's net income of -$20.4M is higher than Humana's net income of -$693M. Notably, Amedisys's price-to-earnings ratio is 69.85x while Humana's PE ratio is 29.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amedisys is 1.29x versus 0.30x for Humana. Usually stocks with elevated PS ratios are considered overvalued.

Option Care Health has a net margin of -3.41% compared to Amedisys's net margin of 4.47%. Amedisys's return on equity of 3.71% beat Option Care Health's return on equity of 14.93%.

Amedisys has a consensus price target of $96.86, signalling upside risk potential of 5.86%. On the other hand Option Care Health has an analysts' consensus of $37.78 which suggests that it could grow by 12.13%. Given that Option Care Health has higher upside potential than Amedisys, analysts believe Option Care Health is more attractive than Amedisys.

Amedisys has a beta of 0.890, which suggesting that the stock is 11.035% less volatile than S&P 500. In comparison Option Care Health has a beta of 1.074, suggesting its more volatile than the S&P 500 by 7.353%.

Amedisys has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Option Care Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amedisys pays -- of its earnings as a dividend. Option Care Health pays out -- of its earnings as a dividend.

Amedisys quarterly revenues are $598.1M, which are smaller than Option Care Health quarterly revenues of $1.3B. Amedisys's net income of -$20.4M is lower than Option Care Health's net income of $60.1M. Notably, Amedisys's price-to-earnings ratio is 69.85x while Option Care Health's PE ratio is 27.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amedisys is 1.29x versus 1.17x for Option Care Health. Usually stocks with elevated PS ratios are considered overvalued.

OptimizeRx has a net margin of -3.41% compared to Amedisys's net margin of -0.24%. Amedisys's return on equity of 3.71% beat OptimizeRx's return on equity of -16.71%.

Amedisys has a consensus price target of $96.86, signalling upside risk potential of 5.86%. On the other hand OptimizeRx has an analysts' consensus of $10.33 which suggests that it could grow by 26.63%. Given that OptimizeRx has higher upside potential than Amedisys, analysts believe OptimizeRx is more attractive than Amedisys.

Amedisys has a beta of 0.890, which suggesting that the stock is 11.035% less volatile than S&P 500. In comparison OptimizeRx has a beta of 1.179, suggesting its more volatile than the S&P 500 by 17.909%.

Amedisys has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OptimizeRx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amedisys pays -- of its earnings as a dividend. OptimizeRx pays out -- of its earnings as a dividend.

Amedisys quarterly revenues are $598.1M, which are larger than OptimizeRx quarterly revenues of $32.3M. Amedisys's net income of -$20.4M is lower than OptimizeRx's net income of -$78K. Notably, Amedisys's price-to-earnings ratio is 69.85x while OptimizeRx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amedisys is 1.29x versus 1.62x for OptimizeRx. Usually stocks with elevated PS ratios are considered overvalued.